Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aukera raises ₹90 crore debt funding to expand lab-grown diamond jewellery business
In a significant move, lab-grown diamond brand Aukera raised ₹90 crore in debt financing, spearheaded by Alteria Capital. This influx of capital is earmarked for enhancing retail presence and advancing product innovation. Aukera's strategy includes opening additional outlets in both familiar and new cities, as the company targets the upscale segment of the booming market, ensuring a robust balance sheet for upcoming industry shifts.
Marksans Pharma rises after acquiring 100% stake in ABCnow GmbH
Marksans Pharma added 3.77% to Rs 270.90 after the company said that it has entered into a definitive agreement to acquire 100% of the share capital of Germany-based ABCnow GmbH.
WhiteOak’s Prashant Khemka stays bullish on healthcare, small NBFCs and manufacturing-led growth
WhiteOak Capital Group Founder Prashant Khemka remains positive on healthcare, citing strong opportunities across pharmaceuticals, hospitals and diagnostics due to the sector's diverse listed companies.
Top picks! Redington among 5 stocks with upside potential of up to 27%. Do you own any?
Monarch Networth Capital has maintained Buy ratings on Pricol, Redington, Sundram Fasteners, Travel Food Services and Viyash Scientific, citing strong earnings growth, improving margins and business expansion. The brokerage sees upside potential of up to 27% across these stocks.
Pulse of the Street: Realty and healthcare lifts markets, but weak rupee clouds rally
Markets rose nearly 1% this week as softer crude oil prices, easing volatility and buying in real estate, healthcare and consumption stocks lifted sentiment. However, weakness in capital goods and power, along with continued pressure on the rupee, showed that the recovery remained selective
MEIL to pump in Rs 40,000 crore capex in 3 years, eyes Rs 2 lakh crore topline in 5 years
Megha Engineering & Infrastructures Limited (MEIL) Group is set to invest up to Rs 40,000 crore in capital expenditure over the next two to three years, targeting a Rs 2 lakh crore topline within five years. The conglomerate plans to take subsidiaries like Evey Trans, its electric bus operator, and its Defence vertical public.
Blue Star Shares In Focus As PL Capital Initiates Coverage — Check Target Price
PL Capital initiates coverage on Blue Star with a bullish view given its strong earnings visibility, improving profitability and leadership across the HVAC industry.
Generics must not be imperiled over data protection: Satish Reddy, Chairman, Dr Reddy's Laboratories
Dr Reddy's chairman, Satish Reddy, has raised concerns about compromising India's competitive edge in generics for foreign investments. He stresses the importance of aligning capital with developmental needs and enhancing collaboration between academia and industry. Advocating for a national mission akin to China's, he highlights the necessity of structured government procurement to stimulate drug innovation and underscores AI's transformative role in drug discovery, contingent on adaptive regulatory systems.
Kotak Institutional removes ABB India, Siemens, Cummins India from model portfolio
Kotak Institutional Equities' Sanjeev Prasad prefers private banks over IT and expensive industrial stocks, citing attractive valuations, stable credit growth and the potential for re-rating. He warned that AI-driven pricing pressure makes it difficult to value IT companies and said investors should avoid chasing richly valued capital goods and electrification stocks despite strong long-term themes. Healthcare, hospitality, retail and telecom remain among his preferred sectors.
Ola Electric Mobility Ltd leads gainers in 'A' group
Morepen Laboratories Ltd, Paras Defence and Space Technologies Ltd, Arvind Ltd and Capri Global Capital Ltd are among the other gainers in the BSE's 'A' group today, 30 June 2026.
Strides Pharma rises after divesting stake in Pivot Path to Ascent Capital consortium
Strides Pharma Science added 2.69% to Rs 1112.30 after the company announced a strategic investment by a consortium led by Ascent Capital, along with co investor Vintage Classic, in its wholly owned subsidiary, Pivot Path.
Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore
Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth by infusing Rs 50 crore for future expansion. Strides will retain a 19.95% stake, while the investors will hold 65.05%. The transaction values Pivot Path at Rs 230 crore post-money.